- Home
- JAZZ vs BECN Comparison
JAZZ vs BECN Comparison
Compare JAZZ & BECN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JAZZ
- BECN
- Stock Information
- Founded
- JAZZ 2003
- BECN 1928
- Country
- JAZZ Ireland
- BECN United States
- Employees
- JAZZ N/A
- BECN N/A
- Industry
- JAZZ Biotechnology: Pharmaceutical Preparations
- BECN RETAIL: Building Materials
- Sector
- JAZZ Health Care
- BECN Consumer Discretionary
- Exchange
- JAZZ Nasdaq
- BECN Nasdaq
- Market Cap
- JAZZ 6.5B
- BECN 5.4B
- IPO Year
- JAZZ 2007
- BECN 2004
- Fundamental
- Price
- JAZZ $113.09
- BECN $95.53
- Analyst Decision
- JAZZ Buy
- BECN Buy
- Analyst Count
- JAZZ 14
- BECN 10
- Target Price
- JAZZ $173.43
- BECN $114.33
- AVG Volume (30 Days)
- JAZZ 496.2K
- BECN 653.3K
- Earning Date
- JAZZ 11-06-2024
- BECN 10-30-2024
- Dividend Yield
- JAZZ N/A
- BECN N/A
- EPS Growth
- JAZZ N/A
- BECN N/A
- EPS
- JAZZ 5.93
- BECN N/A
- Revenue
- JAZZ $3,909,883,000.00
- BECN $9,470,800,000.00
- Revenue This Year
- JAZZ $7.38
- BECN $8.98
- Revenue Next Year
- JAZZ $6.87
- BECN $4.05
- P/E Ratio
- JAZZ $18.79
- BECN N/A
- Revenue Growth
- JAZZ 3.91
- BECN 9.86
- 52 Week Low
- JAZZ $99.06
- BECN $69.94
- 52 Week High
- JAZZ $134.48
- BECN $105.42
- Technical
- Relative Strength Index (RSI)
- JAZZ 52.57
- BECN 56.45
- Support Level
- JAZZ $107.44
- BECN $92.62
- Resistance Level
- JAZZ $112.55
- BECN $95.95
- Average True Range (ATR)
- JAZZ 2.52
- BECN 1.91
- MACD
- JAZZ -0.11
- BECN -0.21
- Stochastic Oscillator
- JAZZ 40.87
- BECN 52.64
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
About BECN Beacon Roofing Supply Inc.
Beacon Roofing Supply Inc manufactures and sells roofing and building materials throughout the United States and Canada. Beacon's key customers consist of contractors, home builders, lumberyards, retailers, wholesale distributors, and building materials suppliers. The company's product portfolio includes both residential and non-residential roofing materials, siding, windows, and waterproofing systems. The majority of revenue is generated from residential and non-residential roofing products. The vast majority of Beacon's revenue comes from the United States.